| Drug ID: | Drug57 |
|---|---|
| Drug Name: | Balsalazide |
| CID: | 54585 |
| DrugBank ID: | DB01014 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT00618228, , NCT00618202 |
| Molecular Formula: | C17H15N3O6 |
| Molecular Weight: | 357.32 g/mol |
| Isomeric SMILES: | C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O |
| Synonyms: | BALSALAZIDE; 80573-04-2; Balsalazido; Balsalazida; Balsalazidum; Balsalazidum [Latin]; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; CHEBI:267413; P80AL8J7ZP; DTXSID7040653 |
| Phase 0: | 0 |
| Phase 1: | 4 |
| Phase 2: | 0 |
| Phase 3: | 2 |
| Phase 4: | 0 |
| Description: | Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK.The chemical name is (E)-5-[[-4-(2-carboxyethyl) aminocarbonyl] phenyl]azo] -2-hydroxybenzoic acid. It is usually administered as the disodium salt.Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine. Its advantage over that drug in the treatment of Ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt521 | 54585 | Balsalazide | 5468 | PPARG | Homo sapiens (human) | Agonist | |
| dt522 | 54585 | Balsalazide | 5743 | PTGS2 | Homo sapiens (human) | Inhibitor | |
| dt523 | 54585 | Balsalazide | 5742 | PTGS1 | Homo sapiens (human) | Inhibitor | |
| dt524 | 54585 | Balsalazide | 240 | ALOX5 | Homo sapiens (human) | Inhibitor | |
| dt525 | 54585 | Balsalazide | None | -- | Bacillus sp. OY1-2 | Substrate | |
| dt526 | 54585 | Balsalazide | 5743 | PTGS2 | Homo sapiens (human) | None | |
| dt527 | 54585 | Balsalazide | 5468 | PPARG | Homo sapiens (human) | None | |
| dt528 | 54585 | Balsalazide | 240 | ALOX5 | Homo sapiens (human) | None | |
| dt529 | 54585 | Balsalazide | 5742 | PTGS1 | Homo sapiens (human) | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT00408174 | Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Inflammatory Bowel Disease|Ulcerative Colitis | DRUG: Balsalazide disodium | Details |
| NCT00269438 | New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: 5 ASA, enemas, suppositories, corticosteroi… | Details |
| NCT00618228 | Bioequivalency Study of Balsalazide Capsules Under Fasting Conditions | None | COMPLETED | Roxane Laboratories | Ulcerative Colitis | DRUG: Balsalazide | Details |
| NCT00618202 | A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions | None | COMPLETED | Roxane Laboratories | Ulcerative Colitis | DRUG: Balsalazide | Details |
| NCT00486031 | Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Inflammatory Bowel Disease|Ulcerative Colitis | DRUG: Balsalazide Disodium | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Radioiodination of balsalazide, bioevaluation, and characterization as a highly…
PMID: 34984721
Year: 2022
Relationship Type:
Association
Score: 6.5
This work focuses on tracking ulcerative colitis in mice. High labeling yield and radiochemical purity were achieved for the formation of a [(125/131…
Balsalazide-Induced Pneumonitis Causing Dyspnea in a Patient With Inflammatory …
PMID: 32309496
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease complications can be related to inflammatory bowel disease-related pulmonary diseases or a form of hypersensitivity pneumo…
Unilateral balsalazide-induced eosinophilic pneumonia in an ulcerative colitis …
PMID: 21127763
Year: 2010
Relationship Type:
Treatment
Score: 6.1
We report a case of unilateral eosinophilic pneumonia secondary to balsalazide monotherapy for ulcerative colitis. After commencing balsalazide, the …
Role of tyrosine 131 in the active site of paAzoR1, an azoreductase with specif…
PMID: 20057057
Year: 2010
Relationship Type:
Mechanism
Score: 6.1
Azoreductase 1 from Pseudomonas aeruginosa strain PAO1 (paAzoR1) catalyses the activation of the prodrug balsalazide and reduces the azo dye methyl r…